Top

Published in:

01-01-2019 | Original Article

Hemangioblastoma in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: a phenotypic overlap between VHL and HLRCC Syndromes

Authors: Eryn Dow, Ingrid M. Winship

Published in: Familial Cancer | Issue 1/2019

Abstract

Hemangioblastomas are rare vascularized central nervous system tumors, which can occur sporadically or be associated with von Hippel Lindau Syndrome. The pathogenesis of hemangioblastomas in von Hippel Lindau Syndrome is proposed to involve a pseudohypoxic intracellular state induced by dysregulation of hypoxia inducible factor alpha due to the absence of von Hippel Lindau protein complex mediated destruction. Dysregulation of fumarate hydratase, a tricarboxylic acid cycle enzyme, occurs in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome due to germline fumarate hydratase gene mutations, and also results in oncogenesis via hypoxia inducible factor alpha dysregulation. We present a case study of hemangioblastoma occurrence in a Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome patient and propose it as possible evidence of a phenotypic overlap between von Hippel Lindau and Hereditary Leiomyomatosis and Renal Cell Cancer Syndromes due to their overlapping role in the biochemical regulation of hypoxia inducible factor alpha.

Pierscianek D, Wolf S, Keyvani K, El Hindy N, Stein KP, Sandalcioglu IE, Sure U, Mueller O, Zhu Y (2017) Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology 37(1):3–11. https://doi.org/10.1111/neup.12316 CrossRefPubMed

Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Handb Clin Neurol 132:139–156. https://doi.org/10.1016/b978-0-444-62702-5.00010-x CrossRefPubMedPubMedCentral

Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98(6):3387–3392. https://doi.org/10.1073/pnas.051633798 CrossRefPubMed

Alam NA, Barclay E, Rowan AJ, Tyrer JP, Calonje E, Manek S, Kelsell D, Leigh I, Olpin S, Tomlinson IP (2005) Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 141(2):199–206. https://doi.org/10.1001/archderm.141.2.199 CrossRefPubMed

Pithukpakorn M, Toro JR (1993) Hereditary leiomyomatosis and renal cell cancer. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews(R). University of Washington, Seattle

Kantaputra PN, Kaewgahya M, Hatsadaloi A, Vogel P, Kawasaki K, Ohazama A, Ketudat Cairns JR (2015) GREMLIN 2 mutations and dental anomalies. J Dent Res 94(12):1646–1652. https://doi.org/10.1177/0022034515608168 CrossRefPubMed

Law R, Dixon-Salazar T, Jerber J, Cai N, Abbasi AA, Zaki MS, Mittal K, Gabriel SB, Rafiq MA, Khan V, Nguyen M, Ali G, Copeland B, Scott E, Vasli N, Mikhailov A, Khan MN, Andrade DM, Ayaz M, Ansar M, Ayub M, Vincent JB, Gleeson JG (2014) Biallelic truncating mutations in FMN2, encoding the actin-regulatory protein Formin 2, cause nonsyndromic autosomal-recessive intellectual disability. Am J Hum Genet 95(6):721–728. https://doi.org/10.1016/j.ajhg.2014.10.016 CrossRefPubMedPubMedCentral

Duong BT, Savarirayan R, Winship I (2016) Incidental diagnosis of HLRCC following investigation for Asperger Syndrome: actionable and actioned. Fam Cancer 15(1):25–29. https://doi.org/10.1007/s10689-015-9829-5 CrossRefPubMed

Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277–285. https://doi.org/10.1038/nrurol.2010.47 CrossRefPubMedPubMedCentral

10.

Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8(2):143–153. https://doi.org/10.1016/j.ccr.2005.06.017 CrossRefPubMed

11.

Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14(15):2231–2239. https://doi.org/10.1093/hmg/ddi227 CrossRefPubMed

12.

Sudarshan S, Shanmugasundaram K, Naylor SL, Lin S, Livi CB, O’Neill CF, Parekh DJ, Yeh IT, Sun LZ, Block K (2011) Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2alpha accumulation and promotes migration and invasion. PLoS ONE 6(6):e21037. https://doi.org/10.1371/journal.pone.0021037 CrossRefPubMedPubMedCentral

13.

Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, Gupta NS, Chitale DA, Kalyana-Sundaram S, Palanisamy N (2017) Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol 41(3):287–298. https://doi.org/10.1097/pas.0000000000000776 CrossRefPubMed

14.

Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1(8):822–826CrossRefPubMed

15.

Lehtonen HJ, Blanco I, Piulats JM, Herva R, Launonen V, Aaltonen LA (2007) Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol 38(5):793–796. https://doi.org/10.1016/j.humpath.2006.10.011 CrossRefPubMed

16.

Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR (2017) Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Clin Genet. https://doi.org/10.1111/cge.13014 CrossRefPubMed

17.

Li M, Song J, Pytel P (2014) Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas. Folia Neuropathol 52(3):234–242CrossRefPubMed

18.

Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, Yamamoto S, Ichimura K, Nakatomi H, Ueki K, Aburatani H, Saito N (2017) Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. Neuro-oncology. https://doi.org/10.1093/neuonc/nox034 CrossRefPubMedPubMedCentral

19.

Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans J, Curry WT, Nahed BV, Shin JH, Paek SH, Park S, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG II, Meyerson M, Getz G, Brastianos PK, Cahill DP (2014) Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. https://doi.org/10.1186/s40478-014-0167-x CrossRefPubMedPubMedCentral

Title: Hemangioblastoma in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: a phenotypic overlap between VHL and HLRCC Syndromes
Authors: Eryn Dow
Ingrid M. Winship
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 1/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-0081-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Sarcoma in neurofibromatosis 2: case report and review of the literature

Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes

Reminders of cancer risk and pain catastrophizing: relationships with cancer worry and perceived risk in women with a first-degree relative with breast cancer

Identification of a novel GREM1 duplication in a patient with multiple colon polyps

Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis

Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer